In particular in T2DM, CST is a promising drug candidate, since it basically targets all characteristics of T2DM and modulates both inflammation and metabolism by lowering blood glucose levels, improving insulin sensitivity and secretion as well as by reducing systemic inflammation (3, 126). The gene discussed is INS; the disease is type 2 diabetes mellitus.